Traders Purchase Large Volume of Call Options on Omeros (NASDAQ:OMER)

Omeros Corporation (NASDAQ:OMER) was the recipient of some unusual options trading activity on Wednesday. Stock investors purchased 7,487 call options on the company. This is an increase of 54% compared to the average daily volume of 4,876 call options.

Insider Activity

In other news, CAO David J. Borges sold 30,000 shares of the company’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $12.31, for a total value of $369,300.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 12.90% of the company’s stock.

Hedge Funds Weigh In On Omeros

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in shares of Omeros by 19.9% in the 4th quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company’s stock valued at $68,929,000 after buying an additional 666,357 shares in the last quarter. UBS Group AG grew its position in shares of Omeros by 213.5% in the 4th quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock worth $38,180,000 after buying an additional 1,513,893 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Omeros by 6.3% during the 4th quarter. Geode Capital Management LLC now owns 1,631,350 shares of the biopharmaceutical company’s stock worth $28,026,000 after acquiring an additional 95,979 shares in the last quarter. State Street Corp lifted its position in Omeros by 26.9% during the fourth quarter. State Street Corp now owns 1,573,526 shares of the biopharmaceutical company’s stock valued at $27,025,000 after acquiring an additional 333,798 shares during the last quarter. Finally, Two Sigma Investments LP lifted its position in Omeros by 39.3% during the third quarter. Two Sigma Investments LP now owns 933,314 shares of the biopharmaceutical company’s stock valued at $3,827,000 after acquiring an additional 263,095 shares during the last quarter. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Wall Street Analyst Weigh In

OMER has been the topic of a number of research reports. Wall Street Zen lowered shares of Omeros from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. D. Boral Capital reissued a “buy” rating and issued a $36.00 price objective on shares of Omeros in a research note on Tuesday, January 27th. HC Wainwright raised their price objective on Omeros from $20.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Omeros in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $40.33.

Omeros Stock Performance

NASDAQ:OMER opened at $10.90 on Friday. The firm has a 50-day simple moving average of $11.38 and a 200-day simple moving average of $9.78. Omeros has a one year low of $2.95 and a one year high of $17.65. The firm has a market cap of $784.80 million, a P/E ratio of -21.80 and a beta of 2.53.

Omeros (NASDAQ:OMER) last issued its quarterly earnings data on Tuesday, March 31st. The biopharmaceutical company reported $3.14 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $3.69. On average, research analysts predict that Omeros will post -3.09 EPS for the current fiscal year.

Key Omeros News

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: Q4 results beat expectations driven by a one‑time Novo Nordisk deal that materially lifted EPS; investors have been upbeat about the earnings surprise and the deal’s cash impact. Omeros Corporation Q4 2025 Earnings Call Summary
• Positive Sentiment: Management says YARTEMLEA is expected to be financially self‑sustaining in 2026 and the company is targeting positive cash flow in 2027 — a clear longer‑term de‑risking catalyst if execution continues. Omeros expects YARTEMLEA to be financially self-sustaining in 2026…
• Positive Sentiment: Unusually large call‑option buying was reported ahead of and around the earnings period, suggesting some traders expect further upside or continued volatility. (Market options flow reported 7,487 calls bought vs a typical ~4,876.)
• Neutral Sentiment: Full earnings‑call transcripts and summaries provide operational context (deal terms, launch timelines, FDA updates) but contain mixed detail; these are useful for assessing whether recent gains are sustainable. Earnings Call Transcript
• Neutral Sentiment: Analyst pieces and bullish case writeups frame a potential upside ahead of Q1 commercial updates, but they also note execution and commercialization milestones that must be met. Making The Bull Case On Q4 Earnings
• Negative Sentiment: Some analyst commentary was mixed, highlighting that the EPS beat was boosted by a one‑time windfall and that forward commercial execution and sustainable revenue proof points will determine longer‑term valuation — potentially tempering enthusiasm. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: After a post‑earnings after‑hours pop tied to the Novo deal and launch optimism, some investors appear to be taking profits or reassessing valuation, which likely contributed to intraday selling pressure. OMER stock surges 5% after-hours

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.